Drug Profile
Adenosine - King Pharmaceuticals
Alternative Names: MEDR 640; PallacorLatest Information Update: 27 Oct 2021
Price :
$50
*
At a glance
- Originator Fujisawa; King Pharmaceuticals Research and Development
- Developer King Pharmaceuticals Research and Development
- Class Anti-ischaemics; Antiarrhythmics; Purine nucleosides; Ribonucleosides; Small molecules
- Mechanism of Action Purinergic P1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Postmyocardial infarction
Most Recent Events
- 19 Feb 2001 Discontinued-III for Postmyocardial infarction in Canada (IV-infusion)
- 19 Feb 2001 Discontinued-III for Postmyocardial infarction in USA (IV-infusion)
- 05 Apr 2000 Adenosine - Medco Research is available for licensing (http://www.kingpharm.com/)